Setterwalls advised Ascelia Pharma in connection with a fully subscribed rights issue of units

Setterwalls has advised Ascelia Pharma AB, listed on Nasdaq Stockholm, in connection with a fully subscribed rights issue of units.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Through the rights issue, Ascelia Pharma receives initial issue proceeds of approximately SEK 105 million before issue costs.